MindMaze Therapeutics Holding SA RLFTY
0.18 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.1779 Day range 0.1779
0.16769 52-week range 4.05
- YTD
- -93.69%
- 1 year
- -88.14%
News
accessnewswire.com Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 RLF-OD032 demonstrated bioequivalence to KUVAN® Powder Study results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF…
accessnewswire.com Relief Therapeutics Publishes 2025 Half-Year Report GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering…
accessnewswire.com Relief Therapeutics Advances Publication of 2025 Half-Year Report GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to…
accessnewswire.com Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination…
accessnewswire.com Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to…
accessnewswire.com Relief Therapeutics Announces Results of Annual General Meeting Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief…
accessnewswire.com Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering…
accessnewswire.com Relief Therapeutics Publishes 2025 Annual General Meeting Agenda GENEVA, SWITZERLAND / ACCESS Newswire / May 15, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative…
accessnewswire.com Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative…
accessnewswire.com Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF)…
accessnewswire.com Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US Sale of GOLIKE® Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 /…
accesswire.com Relief Therapeutics Provides Update on Potential Transaction with Renexxion GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to…
accesswire.com Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU Patients Results Expected to Promote Awareness and Adoption of PKU GOLIKE ® GENEVA, SWITZERLAND / ACCESSWIRE /…
accesswire.com Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation GENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)…
accesswire.com Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering…
accesswire.com Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering…
accesswire.com Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering…
accesswire.com Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 GENEVA, SWITZERLAND / ACCESSWIRE / September 18, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to…
accesswire.com Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering…
accesswire.com Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined…